Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection

Inclusion Criteria: * Post-menarche woman aged 18 to 50 years old (inclusive), * With suspected Bacterial Vaginosis (BV) and/or Vulvovaginal Candidiasis (VVC), presenting symptoms of acute vaginal infection * No clinically significant and relevant abnormalities of medical history (including mental disorders) or physical examination, * Able and willing to participate to the trial by complying with the protocol procedures as evidenced by her dated and signed informed consent form, Exclusion Criteria: * Other already diagnosed or suspected infectious causes of bacterial vaginal infection (e.g., Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae) within 1 month * Current herpes simplex flare-up in the genital area, * Vulvar condyloma due to the human papilloma virus; * Vulvar dermatoses (e.g.: psoriasis or lichenification); * Clinical diagnosis of BV or VVC within 4 months; * Treatment with any antibiotic or antifungal therapy (local or systemic) within 2 months, regardless of the indication; * Treatment with any local treatment (probiotics, antiseptic, etc.) within 1 month, regardless of the indication; * Participant using any intravaginal product (local contraceptive \[spermicide, hormonal ring\], moisturizer, tampon, intimate hygiene product, etc.); * Participant with a chronic disease or condition or treatment known to impact the immune system, including auto-immune disease, diabetes, cancer, renal failure, etc. * Pregnant or breastfeeding patient or intending to become pregnant within 1 month ahead, or having given birth within 3 months; * Participant in perimenopause, i.e. aged 45 years or more, with irregular menstrual cycles that could lead to a suspicion of menopause; * With a known or suspected food allergy or intolerance or hypersensitivity to any of the trial intervention ingredient;